Wave Life Sciences financials
$3.64−0.82%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.7M | $108.3M | $113.3M | $3.6M | $41.0M | $20.1M | $16.0M | $14.4M | $3.9M | $1.1M |
| Gross profit | $42.7M | $108.3M | $113.3M | $3.6M | $41.0M | $20.1M | $16.0M | $14.4M | $3.9M | $1.1M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$215.4M | -$110.4M | -$68.0M | -$162.7M | -$127.0M | -$153.4M | -$208.3M | -$159.5M | -$102.4M | -$55.7M |
| Net income | -$204.4M | -$97.0M | -$57.5M | -$161.8M | -$122.2M | -$149.9M | -$193.6M | -$146.7M | -$102.0M | -$55.7M |
| Net margin | −478.3% | −89.6% | −50.8% | −4434.7% | −298.4% | −746.7% | −1211.5% | −1017.4% | −2619.6% | −5097.1% |
| Diluted EPS | $-1.21 | $-0.70 | $-0.54 | $-2.05 | $-2.36 | $-3.82 | $-5.72 | $-5.06 | $-3.85 | $-2.44 |
| EBITDA | -$211.9M | -$106.5M | -$63.0M | -$156.1M | -$119.5M | -$143.4M | -$199.1M | -$153.9M | -$100.2M | -$54.9M |
| Operating cash flow | -$187.5M | -$151.0M | -$19.4M | -$127.8M | -$89.0M | -$116.0M | -$188.2M | -$22.9M | -$83.7M | -$31.9M |
| Free cash flow | -$188.2M | -$152.0M | -$20.5M | -$129.1M | -$89.6M | -$117.3M | -$192.1M | -$32.8M | -$102.6M | -$37.5M |
| Diluted shares | 168.6M | 138.3M | 106.1M | 78.9M | 51.8M | 39.2M | 33.9M | 29.0M | 26.5M | 22.8M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $602.1M | $302.1M | $200.4M | $88.5M | $150.6M | $184.5M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $638.5M | $352.2M | $274.9M | $146.4M | $207.0M | $279.2M |
| Total liabilities | $112.3M | $134.8M | $227.4M | $183.6M | $166.6M | $188.6M |
| Shareholders' equity | $518.4M | $209.5M | $39.6M | -$45.1M | $32.5M | $82.8M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology